title: Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
abstract: Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.
authors.affiliation: Institute of Biomedical Engineering; National Tsing Hua University ; Hsinchu, Taiwan ; Steele Laboratories for Tumor Biology; Department of Radiation Oncology; Massachusetts General Hospital and Harvard Medical School ; Boston, MA USA.
authors.forename: Yunching
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Steele Laboratories for Tumor Biology; Department of Radiation Oncology; Massachusetts General Hospital and Harvard Medical School ; Boston, MA USA.
authors.forename: Dan G
authors.initials: DG
authors.lastname: Duda
keywords: CXCR4 hepatocellular carcinoma; PD-1; combination therapy; immune checkpoint blockade; immunosuppression